Navigation Links
CareFusion Provides Update on Voluntary Recall of Neurological Monitoring Software and Devices
Date:1/20/2012

SAN DIEGO, Jan. 20, 2012  /PRNewswire/ --CareFusion issued the following update regarding its voluntary recall of the Nicolet® Cortical Stimulator Control Unit, Nicolet® C64 Stimulus Switching Unit (SSU) Amplifier and NicoletOne Software with Cortical Stimulator License. The FDA has classified this action as a Class I recall.

The company initiated the voluntary recall, which affects 125 devices and 58 software licenses, in October 2011. The devices and software subject to the recall were distributed to 38 customers between May 7, 2009 and July 11, 2011. This action has no effect on the manufacture or distribution of current products.

There is no change to the remediation plan previously communicated by the company. CareFusion has already completed the majority of the corrective actions on affected products in the United States.

In October 2011, the company sent an urgent Medical Device Recall Notification to customers stating the identified potential risks associated with the Cortical Stimulator Control Unit, SSU Amplifier and related software applications. Affected units have the potential to develop a short circuit, and affected software licenses may display or capture the incorrect electrode annotation label on the Cortical Stimulator Control Unit screen and in the associated report. A Class I recall is defined as a reasonable probability of serious adverse health consequences or death associated with use of the defective units.

In the notification letter, customers were provided serial and version numbers of affected hardware and software. This information is available at http://www.carefusion.com/customer-support/alerts-notices/medical-device-recall-nicoletone-software.aspx.

Instructions to customers
Customer inquiries related to this action should be addressed to the CareFusion NeuroCare Call Center at 800-356-0007 (press option 2 for Technical Support).

Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA's MedWatch Program: by mail at MedWatch, HF-2, FDA 5600 Fishers Lane, Rockville, MD 20852-9787; by phone at 1-800-332-1088; by fax at 1-800.FDA.0178 or at www.fda.gov/medwatch.

About CareFusion
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined™ services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

 


'/>"/>
SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Receives Federal Data Encryption Certification for Alaris® Infusion System
2. CareFusion Announces Preliminary Second Quarter Results
3. CareFusion Provides Update on Previously Announced Ventilator Recall
4. CareFusion Showcases Medication Management Technologies at American Society for Health-System Pharmacists Conference
5. CareFusion Launches Wireless Diagnostic and Monitoring Neurological Device
6. CareFusion Announces New Ventilation Solution to Help Hospitals Provide Improved Patient Care and Reduce Costs
7. CareFusion Initiates Class I Recall of EnVe Ventilators
8. CareFusion Launches New Emergency Transport Ventilator
9. B. Braun Medical Sues CareFusion for Patent Infringement
10. CareFusion Reports Fourth Quarter and Fiscal 2011 Results
11. CareFusion and ResMed Announce Distribution Agreement for U.S. Hospital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Report Details What ... areas are going to grow at the fastest rates? ... assessing data, trends, opportunities and prospects. Our 190-page ... most lucrative areas in the industry and the future ... sales across the all the major categories of the ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... for Leading Companies – our new study reveals trends, ... issues and events affecting the Alzheimer,s disease therapeutics and ... answer these key questions: - How is the Alzheimer,s ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, ... anti-obesity drugs market is expected to grow at a CAGR ... CAGR of 38.7% in the second half of the forecast period. ... from 2016 to 2027. The market is estimated at $1,058 million ... ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy Network ... of their 503A compounding pharmacy located in Ocala, Florida. , Meeting the ... patients throughout the United States for high-quality human anti-aging and wellness compounded ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic ... in order to make it easier for their readers to get the information they ... impact as well as the techniques used on those particular areas. , “We are ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research ... Li completed his internship in internal medicine at the Emory University and dermatology ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... who administered fillers that resulted in severe facial disfiguration. After four frightening years ... by doctors at UCLA Medical Center, who removed the substances in a partial ...
Breaking Medicine News(10 mins):